Weijie Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weijie Guo has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Xianghuo He
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
12 shared publications Linhui Liang
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
7 shared publicationsQifeng Wang
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China
7 shared publicationsRuopeng Zha
State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Shanghai Jiao Tong University School of Medicine Shanghai China
7 shared publicationsJie Ding
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China
6 shared publicationsMing Yao
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publications
Latest Publications
- Open Access
- 1 February 2018
- Published by Elsevier in Cell Reports
- Vol. 22 (8) , 2016-2025
A LIN28B Tumor-Specific Transcript in Cancer
- 1 February 2018
- Published by Elsevier in Cell Reports
- Vol. 22 (8) , 2016-2025
Open AccessA LIN28B Tumor-Specific Transcript in Cancer
- 1 March 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (S2) , S366-S368
KDM1 links nuclear GSK3β to epigenetic alterations
KDM1 links nuclear GSK3β to epigenetic alterations
- 1 March 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (S2) , S366-S368
KDM1 links nuclear GSK3β to epigenetic alterations
KDM1 links nuclear GSK3β to epigenetic alterations
- Top Cited PapersOpen Access
- 6 April 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 11215
Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs
Circular RNAs (circRNAs) represent a class of widespread and diverse endogenous RNAs that may regulate gene expression in eukaryotes. However, the regulation and function of human circRNAs remain largely unknown. Here we generate ribosomal-depleted RNA sequencing data from six normal tissues and seven cancers, and detect at least 27,000 circRNA candidates. Many of these circRNAs are differently expressed between the normal and cancerous tissues. We further characterize one abundant circRNA derived from Exon2 of the HIPK3 gene, termed circHIPK3. The silencing of circHIPK3 but not HIPK3 mRNA significantly inhibits human cell growth. Via a luciferase screening assay, circHIPK3 is observed to sponge to 9 miRNAs with 18 potential binding sites. Specifically, we show that circHIPK3 directly binds to miR-124 and inhibits miR-124 activity. Our results provide evidence that circular RNA produced from precursor mRNA may have a regulatory role in human cells.
- 6 April 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 11215
Top Cited PapersOpen AccessCircular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs
Circular RNAs (circRNAs) represent a class of widespread and diverse endogenous RNAs that may regulate gene expression in eukaryotes. However, the regulation and function of human circRNAs remain largely unknown. Here we generate ribosomal-depleted RNA sequencing data from six normal tissues and seven cancers, and detect at least 27,000 circRNA candidates. Many of these circRNAs are differently expressed between the normal and cancerous tissues. We further characterize one abundant circRNA derived from Exon2 of the HIPK3 gene, termed circHIPK3. The silencing of circHIPK3 but not HIPK3 mRNA significantly inhibits human cell growth. Via a luciferase screening assay, circHIPK3 is observed to sponge to 9 miRNAs with 18 potential binding sites. Specifically, we show that circHIPK3 directly binds to miR-124 and inhibits miR-124 activity. Our results provide evidence that circular RNA produced from precursor mRNA may have a regulatory role in human cells.
- 1 November 2015
- Published by Elsevier in Gastroenterology
- Vol. 149 (6) , 1587-1598.e11
MicroRNA-124 Reduces the Pentose Phosphate Pathway and Proliferation by Targeting PRPS1 and RPIA mRNAs in Human Colorectal Cancer Cells
- 1 November 2015
- Published by Elsevier in Gastroenterology
- Vol. 149 (6) , 1587-1598.e11
MicroRNA-124 Reduces the Pentose Phosphate Pathway and Proliferation by Targeting PRPS1 and RPIA mRNAs in Human Colorectal Cancer Cells
- Top Cited Papers
- 3 July 2015
- Published by Springer Nature in Cell Research
- Vol. 25 (8) , 981-984
Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis
- 3 July 2015
- Published by Springer Nature in Cell Research
- Vol. 25 (8) , 981-984
Top Cited PapersCircular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis
- 1 July 2015
- Published by Elsevier in Cancer Letters
- Vol. 362 (2) , 208-217
MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer
- 1 July 2015
- Published by Elsevier in Cancer Letters
- Vol. 362 (2) , 208-217
MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer
- Open Access
- 5 June 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1132-1144
MiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer
Cancer cells possess a unique metabolic phenotype that allows them to preferentially utilize glucose through aerobic glycolysis. This phenomenon is referred to as the “Warburg effect.” Accumulating evidence suggests that microRNAs (miRNAs), a class of small noncoding regulatory RNAs, interact with oncogenes/tumor suppressors and induce such metabolic reprograming in cancer cells. To systematically study the metabolic roles of miRNAs in cancer cells, we developed a gain‐of‐function miRNA screen in HeLa cells. Subsequent investigation of the characterized miRNAs indicated that miR‐199a‐5p acts as a suppressor for glucose metabolism. Furthermore, miR‐199a‐5p is often down‐regulated in human liver cancer, and its low expression level was correlated with a low survival rate, large tumor size, poor tumor differentiation status, high tumor‐node‐metastasis stage and the presence of tumor thrombus of patients. MicroRNA‐199a‐5p directly targets the 3′‐untranslated region of hexokinase 2 (HK2), an enzyme that catalyzes the irreversible first step of glycolysis, thereby suppressing glucose consumption, lactate production, cellular glucose‐6‐phosphate and adenosine triphosphate levels, cell proliferation, and tumorigenesis of liver cancer cells. Moreover, HK2 is frequently up‐regulated in liver cancer tissues and associated with poor patient outcomes. The up‐regulation of hypoxia‐inducible factor‐1α under hypoxic conditions suppresses the expression of miR‐199a‐5p and promotes glycolysis, whereas reintroduction of miR‐199a‐5p interferes with the expression of HK2, abrogating hypoxia‐enhanced glycolysis. Conclusion: miR‐199a‐5p/HK2 reprograms the metabolic process in liver cancer cells and provides potential prognostic predictors for liver cancer patients. (Hepatology 2015;62:1132‐1144)
- 5 June 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1132-1144
Open AccessMiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer
Cancer cells possess a unique metabolic phenotype that allows them to preferentially utilize glucose through aerobic glycolysis. This phenomenon is referred to as the “Warburg effect.” Accumulating evidence suggests that microRNAs (miRNAs), a class of small noncoding regulatory RNAs, interact with oncogenes/tumor suppressors and induce such metabolic reprograming in cancer cells. To systematically study the metabolic roles of miRNAs in cancer cells, we developed a gain‐of‐function miRNA screen in HeLa cells. Subsequent investigation of the characterized miRNAs indicated that miR‐199a‐5p acts as a suppressor for glucose metabolism. Furthermore, miR‐199a‐5p is often down‐regulated in human liver cancer, and its low expression level was correlated with a low survival rate, large tumor size, poor tumor differentiation status, high tumor‐node‐metastasis stage and the presence of tumor thrombus of patients. MicroRNA‐199a‐5p directly targets the 3′‐untranslated region of hexokinase 2 (HK2), an enzyme that catalyzes the irreversible first step of glycolysis, thereby suppressing glucose consumption, lactate production, cellular glucose‐6‐phosphate and adenosine triphosphate levels, cell proliferation, and tumorigenesis of liver cancer cells. Moreover, HK2 is frequently up‐regulated in liver cancer tissues and associated with poor patient outcomes. The up‐regulation of hypoxia‐inducible factor‐1α under hypoxic conditions suppresses the expression of miR‐199a‐5p and promotes glycolysis, whereas reintroduction of miR‐199a‐5p interferes with the expression of HK2, abrogating hypoxia‐enhanced glycolysis. Conclusion: miR‐199a‐5p/HK2 reprograms the metabolic process in liver cancer cells and provides potential prognostic predictors for liver cancer patients. (Hepatology 2015;62:1132‐1144)
- Open Access
- 22 May 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1201-1214
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor–induced epithelial‐mesenchymal transition
Hepatocellular carcinoma (HCC) is the third‐most lethal cancer worldwide. Understanding the molecular pathogenesis of HCC recurrence and metastasis is the key to improve patients’ prognosis. In this study, we report that protein tyrosine phosphatase receptor S (PTPRS) is significantly down‐regulated in nearly 80% of HCCs, and its expression negatively correlates with aggressive pathological features, such as larger tumor size and advanced stage. In addition, PTPRS deficiency is independently associated with shorter survival and increased recurrence in patients, although 16.7% of HCCs show intratumor heterogeneous expression of PTPRS. Restoration of wild‐type, but not mutant, PTPRS expression significantly inhibits HCC cell migration and invasion in vitro as well as lung metastasis in vivo, whereas knockdown of its expression significantly promotes invasion and metastasis. Notably, PTPRS‐regulated HCC invasiveness is accompanied by typical changes of epithelial‐mesenchymal transition (EMT). Moreover, PTPRS forms a complex with epithermal growth factor receptor (EGFR) and regulates its tyrosine residues’ phosphorylation. Ectopic expression of EGFR reverses the metastasis‐inhibiting effects of PTPRS, whereas silencing of EGFR or inhibiting phosphorylation of key molecules in EGFR downstream pathways reinhibits EMT and metastasis caused by PTPRS down‐regulation. Meanwhile, promoter hypermethylation of PTPRS is frequently detected in HCC samples and cell lines. Treatment with a demethylation agent, 5‐aza‐2′‐deoxycytidine, recovers PTPRS expression in a dose‐dependent manner. Conclusions: Epigenetic inactivation of PTPRS may increase phosphorylation and activity of EGFR signaling to promote EMT and metastasis in HCC. (Hepatology 2015;62:1201‐1214)
- 22 May 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1201-1214
Open AccessProtein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor–induced epithelial‐mesenchymal transition
Hepatocellular carcinoma (HCC) is the third‐most lethal cancer worldwide. Understanding the molecular pathogenesis of HCC recurrence and metastasis is the key to improve patients’ prognosis. In this study, we report that protein tyrosine phosphatase receptor S (PTPRS) is significantly down‐regulated in nearly 80% of HCCs, and its expression negatively correlates with aggressive pathological features, such as larger tumor size and advanced stage. In addition, PTPRS deficiency is independently associated with shorter survival and increased recurrence in patients, although 16.7% of HCCs show intratumor heterogeneous expression of PTPRS. Restoration of wild‐type, but not mutant, PTPRS expression significantly inhibits HCC cell migration and invasion in vitro as well as lung metastasis in vivo, whereas knockdown of its expression significantly promotes invasion and metastasis. Notably, PTPRS‐regulated HCC invasiveness is accompanied by typical changes of epithelial‐mesenchymal transition (EMT). Moreover, PTPRS forms a complex with epithermal growth factor receptor (EGFR) and regulates its tyrosine residues’ phosphorylation. Ectopic expression of EGFR reverses the metastasis‐inhibiting effects of PTPRS, whereas silencing of EGFR or inhibiting phosphorylation of key molecules in EGFR downstream pathways reinhibits EMT and metastasis caused by PTPRS down‐regulation. Meanwhile, promoter hypermethylation of PTPRS is frequently detected in HCC samples and cell lines. Treatment with a demethylation agent, 5‐aza‐2′‐deoxycytidine, recovers PTPRS expression in a dose‐dependent manner. Conclusions: Epigenetic inactivation of PTPRS may increase phosphorylation and activity of EGFR signaling to promote EMT and metastasis in HCC. (Hepatology 2015;62:1201‐1214)
- Open Access
- 7 October 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (23) , 12083-12096
MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma
MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma
- 7 October 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (23) , 12083-12096
Open AccessMicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma
MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma
- Open Access
- 5 June 2014
- Published by Wiley in Cancer Science
- Vol. 105 (8) , 956-965
MicroRNA‐135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer
The precise functions and mechanisms of microRNAs (miR) in gallbladder cancer (GBC) remain elusive. In this study, we found that miR‐135a‐5p expression is often dampened and correlated with neoplasm histologic grade in GBC. MicroRNA‐135a‐5p introduction clearly inhibited GBC cell proliferation in vitro and in vivo. Moreover, very low density lipoprotein receptor (VLDLR), which is often upregulated in GBC tissues, was identified as a direct functional target of miR‐135a‐5p. Furthermore, the p38 MAPK pathway was proven to be involved in miR‐135a‐VLDLR downstream signaling. Together, these results suggested that the miR‐135a–VLDLR–p38 axis may contribute to GBC cell proliferation.
- 5 June 2014
- Published by Wiley in Cancer Science
- Vol. 105 (8) , 956-965
Open AccessMicroRNA‐135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer
The precise functions and mechanisms of microRNAs (miR) in gallbladder cancer (GBC) remain elusive. In this study, we found that miR‐135a‐5p expression is often dampened and correlated with neoplasm histologic grade in GBC. MicroRNA‐135a‐5p introduction clearly inhibited GBC cell proliferation in vitro and in vivo. Moreover, very low density lipoprotein receptor (VLDLR), which is often upregulated in GBC tissues, was identified as a direct functional target of miR‐135a‐5p. Furthermore, the p38 MAPK pathway was proven to be involved in miR‐135a‐VLDLR downstream signaling. Together, these results suggested that the miR‐135a–VLDLR–p38 axis may contribute to GBC cell proliferation.